Limits...
Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial.

Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, Blackman DJ, Dalby M, Fairbrother KL, Banya W, Wang D, Flather M, Hetherington SL, Kelion AD, Talwar S, Gunning M, Hall R, Swanton H, McCann GP - J. Am. Coll. Cardiol. (2015)

Bottom Line: Patient groups were well matched for baseline clinical characteristics.Although there was no significant reduction in death or MI, a nonsignificant reduction in all primary endpoint components was seen.There was no reduction in ischemic burden on myocardial perfusion scintigraphy or in the safety endpoints of major bleeding, contrast-induced nephropathy, or stroke between the groups.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiovascular Sciences, University of Leicester and National Institute of Health Research Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom. Electronic address: agershlick@aol.com.

No MeSH data available.


Related in: MedlinePlus

Complete Versus Lesion-Only Revascularization in Acute MIOverview of the CvLPRIT trial showing the randomization strategy and main results. CI = confidence interval; CvLPRIT = Complete Versus Lesion-Only Primary PCI trial; HR = hazard ratio; IRA = infarct-related artery; MACE = major adverse cardiac event(s); MI = myocardial infarction; N-IRA = non–infarct-related artery.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4359051&req=5

fig1: Complete Versus Lesion-Only Revascularization in Acute MIOverview of the CvLPRIT trial showing the randomization strategy and main results. CI = confidence interval; CvLPRIT = Complete Versus Lesion-Only Primary PCI trial; HR = hazard ratio; IRA = infarct-related artery; MACE = major adverse cardiac event(s); MI = myocardial infarction; N-IRA = non–infarct-related artery.

Mentions: Among those patients randomized after verbal assent (Central Illustration), the median follow-up was 364 (IQR: 286 to 365) days. Nineteen patients were lost to follow-up (Figure 1). These patients were tracked through a U.K. national database for their vital status, which confirmed that none had died.


Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial.

Gershlick AH, Khan JN, Kelly DJ, Greenwood JP, Sasikaran T, Curzen N, Blackman DJ, Dalby M, Fairbrother KL, Banya W, Wang D, Flather M, Hetherington SL, Kelion AD, Talwar S, Gunning M, Hall R, Swanton H, McCann GP - J. Am. Coll. Cardiol. (2015)

Complete Versus Lesion-Only Revascularization in Acute MIOverview of the CvLPRIT trial showing the randomization strategy and main results. CI = confidence interval; CvLPRIT = Complete Versus Lesion-Only Primary PCI trial; HR = hazard ratio; IRA = infarct-related artery; MACE = major adverse cardiac event(s); MI = myocardial infarction; N-IRA = non–infarct-related artery.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4359051&req=5

fig1: Complete Versus Lesion-Only Revascularization in Acute MIOverview of the CvLPRIT trial showing the randomization strategy and main results. CI = confidence interval; CvLPRIT = Complete Versus Lesion-Only Primary PCI trial; HR = hazard ratio; IRA = infarct-related artery; MACE = major adverse cardiac event(s); MI = myocardial infarction; N-IRA = non–infarct-related artery.
Mentions: Among those patients randomized after verbal assent (Central Illustration), the median follow-up was 364 (IQR: 286 to 365) days. Nineteen patients were lost to follow-up (Figure 1). These patients were tracked through a U.K. national database for their vital status, which confirmed that none had died.

Bottom Line: Patient groups were well matched for baseline clinical characteristics.Although there was no significant reduction in death or MI, a nonsignificant reduction in all primary endpoint components was seen.There was no reduction in ischemic burden on myocardial perfusion scintigraphy or in the safety endpoints of major bleeding, contrast-induced nephropathy, or stroke between the groups.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiovascular Sciences, University of Leicester and National Institute of Health Research Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, United Kingdom. Electronic address: agershlick@aol.com.

No MeSH data available.


Related in: MedlinePlus